Importantly, these cells have no oncogenic RAS or BRAF mutations (Table 1), and PLX4720 conferred no significant proliferative advantage to the tested cells (Figure 1—figure supplement 3) even when used at concentrations that inhibit the proliferation of BRAFV600E melanoma cell lines (Tsai et al., 2008). Here, BRAF is linked to melanoma.